617 related articles for article (PubMed ID: 26637737)
1. The shadowlands of MDS: idiopathic cytopenias of undetermined significance (ICUS) and clonal hematopoiesis of indeterminate potential (CHIP).
Malcovati L; Cazzola M
Hematology Am Soc Hematol Educ Program; 2015; 2015():299-307. PubMed ID: 26637737
[TBL] [Abstract][Full Text] [Related]
2. Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes.
Steensma DP; Bejar R; Jaiswal S; Lindsley RC; Sekeres MA; Hasserjian RP; Ebert BL
Blood; 2015 Jul; 126(1):9-16. PubMed ID: 25931582
[TBL] [Abstract][Full Text] [Related]
3. MDS overlap disorders and diagnostic boundaries.
Tanaka TN; Bejar R
Blood; 2019 Mar; 133(10):1086-1095. PubMed ID: 30670443
[TBL] [Abstract][Full Text] [Related]
4. Clonal Hematopoiesis of Indeterminate Potential.
Heuser M; Thol F; Ganser A
Dtsch Arztebl Int; 2016 May; 113(18):317-22. PubMed ID: 27215596
[TBL] [Abstract][Full Text] [Related]
5. ICUS/CCUS/CHIP: basics & beyond.
Jain M; Tripathi A
Expert Rev Hematol; 2017 Oct; 10(10):915-920. PubMed ID: 28832236
[TBL] [Abstract][Full Text] [Related]
6. CHIP, CCUS, and Other Acronyms: Definition, Implications, and Impact on Practice.
DeZern AE; Malcovati L; Ebert BL
Am Soc Clin Oncol Educ Book; 2019 Jan; 39():400-410. PubMed ID: 31099654
[TBL] [Abstract][Full Text] [Related]
7. ICUS, IDUS, CHIP and CCUS: Diagnostic Criteria, Separation from MDS and Clinical Implications.
Valent P
Pathobiology; 2019; 86(1):30-38. PubMed ID: 29860246
[TBL] [Abstract][Full Text] [Related]
8. Connect MDS/AML: design of the myelodysplastic syndromes and acute myeloid leukemia disease registry, a prospective observational cohort study.
Steensma DP; Abedi M; Bejar R; Cogle CR; Foucar K; Garcia-Manero G; George TI; Grinblatt D; Komrokji R; Ma X; Maciejewski J; Pollyea DA; Savona MR; Scott B; Sekeres MA; Thompson MA; Swern AS; Nifenecker M; Sugrue MM; Erba H
BMC Cancer; 2016 Aug; 16():652. PubMed ID: 27538433
[TBL] [Abstract][Full Text] [Related]
9. Impact of chromosome alterations, genetic mutations and clonal hematopoiesis of indeterminate potential (CHIP) on the classification and risk stratification of MDS.
Ganguly BB; Banerjee D; Agarwal MB
Blood Cells Mol Dis; 2018 Mar; 69():90-100. PubMed ID: 29079134
[TBL] [Abstract][Full Text] [Related]
10. Diagnostic Challenge and Clinical Dilemma: The Long Reach of Clonal Hematopoiesis.
Osman A; Patel JL
Clin Chem; 2021 Aug; 67(8):1062-1070. PubMed ID: 34263288
[TBL] [Abstract][Full Text] [Related]
11. Physician Education: Myelodysplastic Syndrome.
Yoshida Y
Oncologist; 1996; 1(4):284-287. PubMed ID: 10388004
[TBL] [Abstract][Full Text] [Related]
12. [Diagnostics in unclear cytopenia-How and when do we screen for clonal hematopoiesis?].
Haferlach C; Heuser M
Inn Med (Heidelb); 2022 Nov; 63(11):1141-1147. PubMed ID: 36121473
[TBL] [Abstract][Full Text] [Related]
13. How I investigate Clonal cytogenetic abnormalities of undetermined significance.
Tang G; Medeiros LJ; Wang SA
Int J Lab Hematol; 2018 Aug; 40(4):385-391. PubMed ID: 29624895
[TBL] [Abstract][Full Text] [Related]
14. The Clinical Challenge of Idiopathic Cytopenias of Undetermined Significance (ICUS) and Clonal Cytopenias of Undetermined Significance (CCUS).
Steensma DP
Curr Hematol Malig Rep; 2019 Dec; 14(6):536-542. PubMed ID: 31696381
[TBL] [Abstract][Full Text] [Related]
15. MDS-associated somatic mutations and clonal hematopoiesis are common in idiopathic cytopenias of undetermined significance.
Kwok B; Hall JM; Witte JS; Xu Y; Reddy P; Lin K; Flamholz R; Dabbas B; Yung A; Al-Hafidh J; Balmert E; Vaupel C; El Hader C; McGinniss MJ; Nahas SA; Kines J; Bejar R
Blood; 2015 Nov; 126(21):2355-61. PubMed ID: 26429975
[TBL] [Abstract][Full Text] [Related]
16. Challenges in Diagnosing Myelodysplastic Syndromes in the Era of Genetic Testing: Proceedings of the 13th Workshop of the European Bone Marrow Working Group.
Hebeda KM; Tzankov A; Boudova L; Saft L; Hasserjian RP; de Boer M; Fend F; Orazi A; Leguit R
Pathobiology; 2019; 86(1):62-75. PubMed ID: 29982244
[TBL] [Abstract][Full Text] [Related]
17. Idiopathic cytopenia of undetermined significance (ICUS) and idiopathic dysplasia of uncertain significance (IDUS), and their distinction from low risk MDS.
Valent P; Bain BJ; Bennett JM; Wimazal F; Sperr WR; Mufti G; Horny HP
Leuk Res; 2012 Jan; 36(1):1-5. PubMed ID: 21920601
[TBL] [Abstract][Full Text] [Related]
18. Clinical and pathologic challenges of clonal cytopenia of undetermined significance.
Weinberg OK
Int J Lab Hematol; 2021 Jul; 43 Suppl 1():82-85. PubMed ID: 34288451
[TBL] [Abstract][Full Text] [Related]
19. The relationship between idiopathic cytopenias/dysplasias of uncertain significance (ICUS/IDUS) and autoimmunity.
Barcellini W
Expert Rev Hematol; 2017 Jul; 10(7):649-657. PubMed ID: 28586251
[TBL] [Abstract][Full Text] [Related]
20. Special Education: Aplastic Anemia.
Teramura M; Mizoguchi H
Oncologist; 1996; 1(3):187-189. PubMed ID: 10387986
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]